文献速递白血病

伴t(8;21)急性髓系白血病的基因组图谱与克隆演化:一项331例患者的国际研究

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.
PubMed 文献 · Blood · 2019-01-04

该国际研究对331例伴t(8;21)(q22;q22)的急性髓系白血病患者进行了66个复发突变基因的测序,发现95%的患者除t(8;21)外至少存在1个突变,平均每例2.2个驱动突变。表观遗传调控基因突变可能早于信号通路突变发生,KIT高突变(突变水平≥25%)与较差的无复发生存相关(HR 1.96,95%CI 1.22-3.15,P=.005),JAK2、FLT3-ITD高突变和KIT高突变与年龄、白细胞计数一起被确定为总生存的显著预后因素。

要点

  • 95%的t(8;21)患者除融合基因外至少携带1个突变,平均每例2.2个驱动突变。
  • 表观遗传调控基因突变可能早于信号通路突变发生。
  • KIT高突变(≥25%)与较差的无复发生存相关(HR 1.96,95%CI 1.22-3.15,P=.005)。

核心结论

  • 伴t(8;21)急性髓系白血病具有显著的临床和生物学异质性,复发率高达40%。
  • 表观遗传调控基因突变可能早于信号通路突变发生。
  • KIT高突变(突变水平≥25%)与较差的无复发生存相关(HR 1.96,95%CI 1.22-3.15,P=.005)。
  • JAK2、FLT3-ITD高突变和KIT高突变与年龄、白细胞计数一起被确定为总生存的显著预后因素。

研究设计与样本

  • 国际研究,对331例伴t(8;21)(q22;q22)的急性髓系白血病患者进行66个复发突变基因的编码区或热点区域测序。
  • 对56例患者的62份完全缓解样本中的126个突变进行深度测序(约42000×)。
  • 对19对诊断、缓解和复发三份样本进行全外显子测序。

主要发现

  • 95%的患者除t(8;21)外至少存在1个突变,平均每例2.2个驱动突变。
  • 复发突变见于RAS/RTK信号通路相关基因(63.4%)、表观遗传调控基因(45%)、黏连蛋白复合体(13.6%)、MYC信号通路(10.3%)和剪接体(7.9%)。
  • 研究新发现了GIGYF2、DHX15和G2E3基因的突变。
  • 在34%的RAS/RTK突变患者中,识别出同一通路中的多个突变。
  • 在12例患者中识别出16个持续存在的突变,其中5例在定量聚合酶链反应分析中缺乏RUNX1-RUNX1T1。

关键数值与推荐

  • KIT高突变定义为突变水平≥25%。
  • KIT高突变与较差的无复发生存相关(HR 1.96,95%CI 1.22-3.15,P=.005)。
  • 多因素分析中,JAK2、FLT3-ITD高突变和KIT高突变为总生存的显著预后因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia with t(8;21)(q22;q22) is characterized by considerable clinical and biological heterogeneity leading to relapse in up to 40% of patients. We sequenced coding regions or hotspot areas of 66 recurrently mutated genes in a cohort of 331 t(8;21) patients. At least 1 mutation, in addition to t(8;21), was identified in 95%, with a mean of 2.2 driver mutations per patient. Recurrent mutations occurred in genes related to RAS/RTK signaling (63.4%), epigenetic regulators (45%), cohesin complex (13.6%), MYC signaling (10.3%), and the spliceosome (7.9%). Our study identified mutations in previously unappreciated genes: GIGYF2, DHX15, and G2E3 Based on high mutant levels, pairwise precedence, and stability at relapse, epigenetic regulator mutations were likely to occur before signaling mutations. In 34% of RAS/RTKmutated patients, we identified multiple mutations in the same pathway. Deep sequencing (∼42 000×) of 126 mutations in 62 complete remission samples from 56 patients identified 16 persisting mutations in 12 patients, of whom 5 lacked RUNX1-RUNX1T1 in quantitative polymerase chain reaction analysis. KIT high mutations defined by a mutant level ≥25% were associated with inferior relapse-free survival (hazard ratio, 1.96; 95% confidence interval, 1.22-3.15; P = .005). Together with age and white blood cell counts, JAK2, FLT3-internal tandem duplicationhigh, and KIT high mutations were identified as significant prognostic factors for overall survival in multivariate analysis. Whole-exome sequencing was performed on 19 paired diagnosis, remission, and relapse trios. Exome-wide analysis showed an average of 16 mutations with signs of substantial clonal evolution. Based on the resemblance of diagnosis and relapse pairs, genetically stable (n = 13) and unstable (n = 6) subgroups could be identified.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Christen F, Hoyer K, Yoshida K, et al. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood. 2019. PMID: 30610028. doi:10.1182/blood-2018-05-852822

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。